WallStreetZenWallStreetZen

NASDAQ: NVAX
Novavax Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NVAX

Based on 3 analysts offering 12 month price targets for Novavax Inc

Min Forecast
$8.00-21.57%
Avg Forecast
$14.33+40.52%
Max Forecast
$19.00+86.27%

Should I buy or sell NVAX stock?

Based on 3 analysts offering ratings for Novavax Inc.

Buy
Strong Buy
2 analysts 66.67%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
1 analysts 33.33%
Our proven Zen Rating quant model agrees with analyst consensus with a "Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their NVAX stock forecasts and price targets.

NVAX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-11-06
lockedlocked$00.00+00.00%2026-10-15
lockedlocked$00.00+00.00%2026-06-11

1 of 1

Forecast return on equity

Is NVAX forecast to generate an efficient return?

Company
-9.31%
Industry
18.06%
Market
161.1%
NVAX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NVAX forecast to generate an efficient return on assets?

Company
2.27%
Industry
19.62%
NVAX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NVAX earnings per share forecast

What is NVAX's earnings per share in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
-$0.28
Avg 2 year Forecast
-$0.50
Avg 3 year Forecast
$0.05

NVAX revenue forecast

What is NVAX's revenue in the next 3 years based on estimates from 10 analysts?

Avg 1 year Forecast
$487.8M+18.5%
Avg 2 year Forecast
$255.4M-37.95%
Avg 3 year Forecast
$232.9M-43.43%
NVAX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

NVAX revenue growth forecast

How is NVAX forecast to perform vs Biotechnology companies and vs the US market?

Company
-17.3%
Industry
28.18%
Market
12.17%
NVAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
NVAX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

NVAX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NVAX$10.20$14.33+40.52%Buy
SLS$8.37N/AN/A
IMCR$32.38$55.00+69.86%Buy
NBTX$32.87$55.00+67.33%Strong Buy
ABSI$9.97$15.11+51.56%Strong Buy
View Top Biotech Stocks

Novavax Stock Forecast FAQ

Is Novavax Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: NVAX) stock is to Buy NVAX stock.

Out of 3 analysts, 2 (66.67%) are recommending NVAX as a Strong Buy, 0 (0%) are recommending NVAX as a Buy, 0 (0%) are recommending NVAX as a Hold, 0 (0%) are recommending NVAX as a Sell, and 1 (33.33%) are recommending NVAX as a Strong Sell.

If you're new to stock investing, here's how to buy Novavax stock.

What is NVAX's earnings growth forecast for 2026-2028?

(NASDAQ: NVAX) Novavax's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.6%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.59%.

Novavax's earnings in 2026 is -$76,727,000.On average, 10 Wall Street analysts forecast NVAX's earnings for 2026 to be -$46,285,027, with the lowest NVAX earnings forecast at -$63,066,443, and the highest NVAX earnings forecast at -$13,860,757. On average, 10 Wall Street analysts forecast NVAX's earnings for 2027 to be -$82,834,523, with the lowest NVAX earnings forecast at -$218,306,919, and the highest NVAX earnings forecast at $60,640,811.

In 2028, NVAX is forecast to generate $8,085,441 in earnings, with the lowest earnings forecast at -$95,408,209 and the highest earnings forecast at $131,677,189.

What is NVAX's revenue growth forecast for 2026-2028?

(NASDAQ: NVAX) Novavax's forecast annual revenue growth rate of -17.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 28.18%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.17%.

Novavax's revenue in 2026 is $411,649,000.On average, 10 Wall Street analysts forecast NVAX's revenue for 2026 to be $80,491,394,590, with the lowest NVAX revenue forecast at $65,912,848,645, and the highest NVAX revenue forecast at $100,561,440,355. On average, 10 Wall Street analysts forecast NVAX's revenue for 2027 to be $42,146,601,079, with the lowest NVAX revenue forecast at $25,873,412,611, and the highest NVAX revenue forecast at $58,731,656,573.

In 2028, NVAX is forecast to generate $38,425,647,926 in revenue, with the lowest revenue forecast at $15,756,710,269 and the highest revenue forecast at $64,695,082,159.

What is NVAX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NVAX) forecast ROA is 2.27%, which is lower than the forecast US Biotechnology industry average of 19.62%.

What is NVAX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year NVAX price target, the average NVAX price target is $14.33, with the highest NVAX stock price forecast at $19.00 and the lowest NVAX stock price forecast at $8.00.

On average, Wall Street analysts predict that Novavax's share price could reach $14.33 by Nov 6, 2027. The average Novavax stock price prediction forecasts a potential upside of 40.52% from the current NVAX share price of $10.20.

What is NVAX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NVAX) Novavax's current Earnings Per Share (EPS) is -$0.46. On average, analysts forecast that NVAX's EPS will be -$0.28 for 2026, with the lowest EPS forecast at -$0.38, and the highest EPS forecast at -$0.08. On average, analysts forecast that NVAX's EPS will be -$0.50 for 2027, with the lowest EPS forecast at -$1.32, and the highest EPS forecast at $0.37. In 2028, NVAX's EPS is forecast to hit $0.05 (min: -$0.58, max: $0.80).

What is NVAX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NVAX) forecast ROE is -9.31%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.